**Abstract**

Down syndrome (DS) is the most common chromosomal aberration and genetically determined cause of intellectual disability. DS patients often present with some congenital defects and chronic diseases, including early onset dementia, which affects 70% of DS patients over 55 years of age and has a clinical presentation similar to Alzheimer disease (AD). The symptoms of DS originate from excessive genetic material within the “critical region” of the 21st chromosome. The “critical region” encompasses genes potentially associated with increase risk of dementia, e.g. the APP gene (amyloid beta precursor protein) which leads to excessive amyloid beta production. Post-mortem studies of DS patients’ brains revealed diffuse deposition of the insoluble form of amyloid beta (Aβ), which is a characteristic feature of AD. Moreover, those changes were commonly observed in subjects > 31 years old. The pathomechanisms of AD have not been fully elucidated and scientists are still searching for new risk factors that may contribute to the development of this common illness. Recent research proved that lipid disturbance, especially disorders in the metabolism of HDL (high density lipoprotein) may play a crucial role in this pathogenic process. There are many studies examining lipid and lipoprotein concentration in the DS population, but up to now there are insufficient studies comparing these parameters with memory impairment, which may be a useful model for better understanding of the dementia pathomechanism.

**Key words:** Down syndrome, Alzheimer disease, dementia, lipids

---

**Streszczenie**

Zespół Downa jest najczęstszą aberracją chromosomową oraz najczęstszą przyczyną niepełnosprawności intelektualnej uwarunkowanej genetycznie. U pacjentów z zespołem Downa częściej występują wady wrodzone oraz choroby przewlekłe, takie jak wczesne otępienie, które dotyczą około 70% pacjentów powyżej 55 roku życia, a przebiegiem klinicznym przypomina chorobę Alzheimera (AD). Objawy charakterystyczne dla zespołu Downa są spowodowane nadmiarem materiału genetycznego zawartego w tzw. “regionie krytycznym” 21. chromosomu. Ten „region krytyczny” zawiera gene związane z rozwojem otępienia, między innymi gen APP (ang. Amyloid beta precursor protein) kodujący białko prekursowane dla amyloidu beta (Aβ), którego nadmiar może skutkować zwiększoną produkcją Aβ. Badania pośmiertne mózgów pacjentów z zespołem Downa wykazały obecność rozlanych złogów nierozpuszczalnej formy Aβ, co jest jedną z charakterystycznych cech AD. Ponadto zmiany te występowały powszechnie u pacjentów powyżej 31 roku życia. Patomechanizmy rozwoju AD nie zostały do końca poznane i naukowcy nieustannie poszukują nowych czynników ryzyka, które mogą wpływać na rozwój tej częstej choroby. Ostatnie badania pokazują że zaburzenia gospodarki lipidowej, w szczególności dotyczące HDL (ang. High-density lipoprotein) mogą odgrywać znaczącą rolę w patogenezie AD. W piśmiennictwie dostępnych jest wiele prac dotyczących poziomu lipidów...
INTRODUCTION

Down syndrome (DS) is the most common chromosomal aberration and genetically determined cause of intellectual disability (ID). The occurrence of DS ranges between 1:625-1:847 live births [1, 2]. Besides ID, weak muscle tone and characteristic dysmorphism, DS patients commonly present with some congenital defects, including cardiac (40-50%) and gastrointestinal (about 12%) malformations. Moreover, other diseases are more prevalent in DS patients as compared to the general population, such as obesity, hypothyroidism, type 1 and 2 diabetes, coeliac disease, leukaemia and dementia [3]. Despite the increased risk of chronic disease, life expectancy of DS patients is continuously increasing. This can be explained not only by the growing number of successful pregnancies and deliveries by women aged >36, but mainly by the surgical correction of cardiac defects and the possibility of treatment of chronic conditions [4, 5]. In developed countries up to 96% DS children survive the 1st year of life if they do not suffer from congenital heart defects. The rate drops to 80% when heart defects are present [6].

Currently, the mean life expectancy of DS patients reaches 55-60 years [6]. Because of this prolonged life expectancy, the overall medical profiles of DS patients have changed, as well as their healthcare needs. Available research results emphasize the significance to understand the development of early-onset dementia as well as obesity and metabolic disturbances in DS subjects, which can simultaneously lead to cerebral destruction and cerebrovascular problems and have a great impact on the quality of life among DS subjects and their families [7, 10].

DS SYNDROME AND INCREASE RISK OF DEMENTIA

More than 70% of DS patients surviving up to the age of 55-60 demonstrate early-onset dementia, which clinically presents with similar features to Alzheimer’s disease (AD-like disease) [3].

AD is a progressive neurodegenerative disorder with more than 30 million individuals affected worldwide. It is estimated that in the U.S. 12% of the people aged >65 will develop AD, with the percentage rising to 45% for individuals aged >80. Early signs of the disease consist of loss of short-term memory, learning ability, and linguistic fluency. Later on, disorders of long-term, semantic, and procedural memory follow. Finally, patients become fully dependent, losing basic skills such as the ability to move or eat. Patients diagnosed over the age of 65 are classified as late-onset (LOAD – late-onset AD), and those diagnosed under the age of 65 – early-onset (EOAD – early-onset AD). Among EOAD patients, a small group suffers from a familial form of the disease (EOFAD – early-onset familial AD) which is associated with amyloid beta precursor (APP) gene mutation or other presenilin genes. EOFAD cases represent only 5% of all AD patients, however studying the EOFAD defective genes has provided further insight into AD pathology [11].

The clinical presentation of DS originates from excessive genetic material carried by an additional full 21 chromosome or its partial trisomy. Research focusing on the “critical region” genes has helped to understand how excess of certain proteins affects the phenotypical features in DS and has been crucial to establishing genotype-phenotype correlation.

The “critical region” encompasses more than 630 different genes, among them genes potentially associated with dementia development:
- APP (amyloid beta precursor) which, if overly expressed, leads to excessive amyloid beta (Aβ) production;
- SOD1 (Superoxide dismutase1) gene encoding superoxide dismutase which in excess destabilizes oxidoreductive balance and leads to premature aging, as well as immune disturbances;
- CBS (Cystatione beta-synthetase) gene associated with homocysteine metabolism;
- DYRK1A (Dual spec! city tyrosine-phosphorylation-regulated kinase) gene coding the enzyme DYRK1A catalyzing autophosphorylation on serine-threonine kinases, important in synaptic transmission [12].

One of the characteristic features of AD is the deposition of the so-called senile plaques in the brain, which include the insoluble form of Aβ. In a study of 29 DS patients aged 3-72 years amyloid deposits were already discovered in a 12 year-old child, and appeared universally in participants >31 years old. Post-mortem studies of DS brains reveal diffuse Aβ42 (a beta ending at amino acid 42) deposits and progressing to compacted, fibrillar plaques often containing Aβ40 (a beta ending at amino acid 40) that was associated with neurodegeneration [13]. The distribution of fibrillary plaques and neurofibrillary tangles in DS brains is very similar to AD, although the density is greater in DS [14]. Henceforth, DS patients seem to be a certain “clinical model” for AD research.
OTHER RISK FACTORS FOR AD DEVELOPMENT

The pathomechanisms of AD have not been fully elucidated. It has been found that it is linked to both genetic and environmental factors, such as the lack of physical activity, cerebral hyperfusion, abnormal glucose metabolism, oxidation-reduction imbalance or inflammatory processes [3, 11]. Risk factors for LOAD that have been known for a while include old age, a family history of dementia, and possession of one or more APOE e4 alleles [15].

Recently, scientists proved that lipid disturbances can also be connected with the development of AD. Inter alia, an inverse correlation between the levels of Aβ and the concentration of high density lipoprotein (HDL) cholesterol in plasma has been observed [16, 17].

HDL is one of the major carriers of cholesterol in blood. Through its key role in reverse cholesterol transport, anti-inflammatory, antiaggregatory and antioxidant activities, it influences cardiovascular health in a positive way. Numerous epidemiological studies have shown that lifestyle interventions proven to increase HDL levels also provide neuroprotective effects [18, 19]. Moreover, elevated HDL levels are also associated with longevity, improved cognition and dementia-free survival [20]. HDL is the smallest and densest amongst lipoproteins. It is composed of an outer layer containing free cholesterol, phospholipids, and various apolipoproteins (Apo), and a hydrophobic core composed of triglycerides and cholesterol esters. HDL is particularly rich in Apo A-I and Apo A-II apolipoproteins. Apo A-IV, Apo C, and Apo E are also present [21]. Human cerebrospinal fluid (CSF) contains spherical lipoproteins resembling HDL in human plasma. Apo E and A-I are the major human CSF apolipoproteins. Astrocytes synthesize ApoE-rich HDL locally, while Apo A-I-rich HDL are derived from plasma HDL crossing the blood-brain barrier [22].

The relationship between HDL level, Aβ and brain function seems to be significant. Aβ production depends on cholesterol content in cellular membranes. HDL is able to suppress amyloid production by decreasing cellular cholesterol via activation of reverse cholesterol transport mediated by ABC transporters [23]. It is also known that HDL carries Aβ in CSF and plasma, and can directly bind the excess amyloid peptide which results in the inhibition of its assembly into fibrils [24]. Additionally, HDL can remove Aβ accumulated in vascular walls in the course of vascular dementia development, as well as reduce oxidative stress and thus indirectly reduce amyloid production [25]. The monomeric form of Aβ is a strong chelator of pro-oxidant metal ions and its production is enhanced by oxidative stress.

The relationship between HDL concentration and memory was investigated by the Whitehall II Study. A group of 3673 middle-aged adults was examined, and the results suggested a clear association between low plasma level of HDL and poor memory. Furthermore, decreased HDL was associated with decline in memory function over a 5-year long follow-up. The patients’ education, occupation, chronic diseases, or medication use did not change the results, and neither did the APOE e4 status. Serum levels of total cholesterol and triglycerides presented no link to memory deficit or decline. The study identified HDL molecules as important for memory, and low HDL in the middle-aged population as an important risk factor for dementia development later on [26]. However, some researchers studying the elderly population connected low HDL concentration with vascular dementia but not with AD [27]. Such equivocal findings may be explained by dementia itself modifying lipid levels [28]. In the future, it might be necessary to assay lipid concentrations before diagnosing dementia.

Other studies have shown that atherosclerosis and atherosclerosis – related diseases, such as coronary artery disease (CAD), or type II diabetes mellitus are also associated with LOAD [29]–[31]. In a 1990 study, abundant senile plaques were found in the brains of non-demented patients dying with or as a result of critical CAD (75%) compared to non-heart disease subjects (12%) [29]. It is now recognized that individuals with heart diseases often have demonstrable AD-like Aβ deposits within neurons in the brain and that cerebral atherosclerosis is strongly associated with an increase frequency of neurotic plaques [32].

HOW DOES THIS RELATE TO THE AD – LIKE DISEASE IN DS?

In the past, individuals suffering from DS were considered protected from atherosclerotic disease, one of the factors predisposing to AD. Murdoch described a complete lack of atherosclerosis in five institutionalized DS patients, and classified DS as an “atheroma-free” disease model [33]. A series of subsequent post mortem studies demonstrated lower atheroma incidence in institutionalized DS patients as compared to controls of the same age [7, 34]. Nevertheless, there are also opposing reports not supporting DS as an “atheroma-free” disease model. Autopsy material coming from institutionalized children and adolescents <21 years of age with intellectual disability reveals slightly more advanced atherosclerosis of coronary arteries and aortas as compared to other study subjects [8]. Recent data collected by two statistically significant epidemiological studies targeting DS patients suggests an increased mortality risk due to ischemic heart disease and cerebrovascular disease in comparison with the general population. Scientists from Sweden and Denmark noted that individuals suffering from DS have a 3.9-fold higher predisposition to dying from ischemic heart disease [35]. Another epidemiological study of >14 000 individuals from California found a similar 4.3-fold increase of mortality due to ischemic heart disease [36]. As it was mentioned before, coronary artery disease remains one of the risk factors for AD.

Many research projects focused on comparing lipid and lipoprotein concentrations in DS and non-DS groups, however, produced equivocal conclusions [9, 37–41]. The aforementioned studies varied significantly in their size, specific outcomes, and control groups. Only two of them discuss the association of DS with an unfavorable lipid profile independent of the individuals’ body mass. One
cross-sectional study observed prepubertal participants (aged 4-10) with BMI below the 95th percentile for their age and sex focusing on lipid profiles, and compared the results with those of their non-DS siblings. Children with DS had higher total cholesterol, LDL, TG, and lower HDL than their siblings, the outcomes did not vary depending on body mass [40]. This is in agreement with our own initial results. We have compared serum lipid profiles, total cholesterol, LDL, TG and HDL level in 34 children with DS and 31 non-DS children aged from 8 to 18 years. Children with DS had higher TC (difference 15 mg/dl), LDL (19.9 mg/dl), TG (23.6 mg/dl) after adjustment for age, gender and BMI. We did not notice a significant difference in HDL levels in this group. Another study targeted DS fetuses at 18-36 weeks of gestation. Gestational age, size, and number of subjects were taken into account. DS fetuses exhibited significantly higher cholesterol levels [41]. Congenital heart disease, hypothyroidism, body mass, glucose levels, and insulin levels alone are unlikely to explain the difference between healthy and DS children's lipid profiles. The possible influence of chromosome 21 overexpression influencing the lipid profile remains a question yet to be answered.

No studies linking lipid concentrations and memory in DS patients are currently available. As mentioned before, Aβ deposition in DS patients' central nervous system was seen as early as at the age of 12, and became universal by the age of 31. It is important to develop studies focusing on children and young adults with DS, because their results might appear beneficial in understanding the correlation between lipid metabolism and dementia.

REFERENCES

1. Weijerman ME, van Furth AM, Vonk Noordegraaf A, van Wouwe JP, Broers CJM, Gemke RJBJ. Prevalence, neonatal characteristics, and first-year mortality of Down syndrome: a national study. J Pediatr. Jan 2008;vol. 152, no. 1:15-19.
2. Shin M, Besser LM, Kucik JE, Lu C, Siffel C, Correa A. Prevalence of Down syndrome among children and adolescents in 10 regions of the United States. Pediatrics Dec 2009;vol. 124, no. 6:1565-1571.
3. Wilcock DM, Griffin WST. Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J Neuroinflammation 2013;vol. 10:84.
4. Weijerman ME, Broers CJM, van der Plas RN. New insights into the support of children with Down syndrome. Ned. Tijdschr. Geneeskd. 2013;vol. 157, no. 6:A5330.
5. Hiji T, Fukushima J, Igarashi H, Takahashi N, Ueda K. Life expectancy and social adaptation in individuals with Down syndrome with and without surgery for congenital heart disease. Clin Pediatr. (Philia). Jun 1997;vol. 36, no. 6:327-332.
6. Bittles AH, Glasson EJ. Clinical, social, and ethical implications of changing life expectancy in Down syndrome. Dev Med Child Neurol. Apr 2004;vol. 46, no. 4:282-286.
7. Yla-Herttuala S, Luoma J, Nikkari T, Kivimaki T. Down's syndrome and atherosclerosis. Atherosclerosis Apr 1989;vol. 76, no. 2-3:269-272.
8. Chaney RH. Neurogenic atherosclerosis in mentally retarded persons. J Ment Defic Res. Sep 1987;vol. 31 (Pt 3):235-240.
9. Pueschel SM, Craig WY, Haddow JE. Lipids and lipoproteins in persons with Down's syndrome. J Intellect Disabil Res. Aug 1992;vol. 36 (Pt 4):365-369.
10. Lott IT, Head E. Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging Mar 2005;vol. 26, no. 3:383-389.
11. Martins II, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, Nolan D, Gandy SE, Martins RN. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry Aug 2006;vol. 11, no. 8:721-736.
12. Wierzbz K. Zespół Downa i medycyna : praca zbiorowa. Warszawa : Stowarzyszenie Rodzin i Opiekunów Osób z Zespołem Downa Bardziej Kociani, 2014.
13. Lemere CA, Bluszcz JK, Yamaguchi H, Wisniewski T, Saito TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis. Feb 1996;vol. 3, no. 1:16-32.
14. Hof PR, Bouras C, Perl DP, Sparks, DL Mehta NA, Morrison JH. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Quantitative regional analysis and comparison with Alzheimer's disease. Arch Neurol. Apr 1995;vol. 52, no. 4:379-391.
15. Rocca WA, Amaducci LA, Schoenberger BS Epidemiology of clinically diagnosed Alzheimer's disease. Ann Neurol. May 1986;vol. 19, no. 3:415-424.
16. Mayeux R, Honig LS, Tang M-X, Manly J, Stern Y, Schupf N, Mehta PD. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology Nov 2003;vol. 61, no. 9:1185-1190.
17. Bates KA, Sohrabi HR, Rodrigues M, Bellby J, Dhaliwal SS, Taddei K, Criddle A et al. Association of cardiovascular factors and Alzheimer's disease plasma amyloid-beta protein in subjective memory complainers. J Alzheimer Dis. 2009;vol. 17, no. 2:305-318.
18. Ward MA, Carlsson CM, Trivedi MA, Sager MA, Johnson SC. The effect of body mass index on global brain volume in middle-aged adults: a cross sectional study. BMC Neurol. Dec 2005;vol. 5:23.
19. Kramer AF, Erickson KI, Colcombe SJ. Exercise, cognition, and the aging brain. J Appl Physiol. Oct 2006;vol. 101, no. 4:1237-1242.
20. Barzilai N, Atzmon G, Derby CA, Bauman JM, Lipton RB. A genotype of exceptional longevity is associated with preservation of cognitive function. Neurology Dec 2006;vol. 67, no. 12:2170-2175.
21. McGrowder D, Riley C, Morrison EYSA, Gordon L. The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer. Cholesterol 2011;vol. 2011:496925.
22. Kontush A, Chapman MJ, HDL: close to our memories? Arteriosclerosis, thrombosis, and vascular biology. Aug 2008;vol. 28, no. 8. United States:1418-1420.
23. Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. Feb 2008;vol. 118, no. 2:671-682.
24. Olesen OF, Dago L. High density lipoprotein inhibits assembly of amyloid beta-peptides into fibrils. Biochem Biophys Res Commun. Apr 2000;vol. 270, no. 1:62-66.
25. Hardy J, Cullen K. Amyloid at the blood vessel wall. Nature medicine, Jul 2006; vol. 12, no. 7. United States:756-757.

26. Singh-Manoux A, Gimeno D, Kivimaki M, Brunner E, Marmot MG. Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study. Arterioscler Thromb Vasc Biol. Aug 2008; vol. 28, no. 8:1556-1562.

27. Reitz C, Tang M-X, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol. May 2004; vol. 61, no. 5:705-714.

28. Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology, Mar 2007; vol. 68, no. 10:751-756.

29. Sparks DL, Hunsaker JC3rd, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging, 1990; vol. 11, no. 6:601-607.

30. Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord. Feb 2003; vol. 27, no. 2:260-268.

31. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. Oct 2001; vol. 154, no. 7:635-641.

32. Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology, Feb 2005; vol. 64, no. 3:494-500.

33. Murdoch JC, Rodger JC, Rao SS, Fletcher CD, Dunnigan MG. Down's syndrome: an atheroma-free model? Br Med J. Jul 1977; vol. 2, no. 6081:226-228.

34. Brattstrom L, Englund E, Brun A. Does Down syndrome support homocysteine theory of arteriosclerosis? Lancet (London, England), Feb 1987; vol. 1, no. 8529. ENGLAND:391-392.

35. Hill DA, Gridley G, Cnattingius S, Mellemkjaer L, Linet M, Adami H-O, Olsen JH, Nyren O, Fraumeni JF. "Mortality and cancer incidence among individuals with Down syndrome. Arch Intern Med. Mar 2003; vol. 163, no. 6:705-711.

36. Day SM, Strauss DJ, Shavelle RM, Reynolds RJ. Mortality and causes of death in persons with Down syndrome in California. Dev Med Child Neurol. Mar 2005; vol. 47, no. 3:171-176.

37. Dorner K, Gaethike AS, Tolksdorf M, Schumann KP, Gustmann H. Cholesterol fractions and triglycerides in children and adults with Down's syndrome. Clin Chim Acta. Oct 1984; vol. 142, no. 3:307-311.

38. Salo MK, Solakivi-Jaakkola T, Kivimaki T, Nikkari T. Plasma lipids and lipoproteins in Down's syndrome. Scand J Clin Lab Invest. Sep 1979; vol. 39, no. 5:485-490.

39. Zamorano A, Guzman M, Aspillaga M, Avendano A, Gatica M. Concentrations of serum lipids in children with Down's syndrome. Arch Biol Med Exp. (Santiago). 1991; vol. 24, no. 1:49-55.

40. Adelekan T, Magge S, Shults J, Stallings V, Stettler N. Lipid profiles of children with Down syndrome compared with their siblings. Pediatrics, Jun 2012; vol. 129, no. 6:e1382-1387.

41. Bocconi L, Nava S, Fogliani R, Nicolini U. Trisomy 21 is associated with hypercholesterolemia during intrauterine life. Am J Obstet Gynecol., Mar 1997; vol. 176, no. 3:540-543.

Author's contributions/Wkład Autorów
According to the order of the Authorship/Według kolejności

Conflicts of interest/Konflikt interesu
The Authors declare no conflict of interest.
Autorzy pracy nie zgłaszają konfliktu interesów.

Received/Nadesłano: 04.01.2017 r.
Accepted/Zaakceptowano: 24.01.2017 r.

Published online/Dostępne online

Address for correspondence:  
Anna Kłosowska  
ul. Malczewskiego 7/39, 80-107 Gdańsk  
phone: 508-118-759  
e-mail: a.kobierecka@gmail.com